Morgan Stanley’s Biolase, Inc. BIOL Stock Holding History

Morgan Stanley’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-28	Closed	-$32	–	8021
2023 Q4	$32	Buy	28 +11	+65%	+$16	﹤0.01%	7732
2023 Q3	$32	Buy	17 +7	+70%	+$37	﹤0.01%	7511
2023 Q2	$73	Sell	10 -3	-23%	-$50	﹤0.01%	7515
2023 Q1	$363	Sell	13 -20	-61%	-$973	﹤0.01%	7466
2022 Q4	$2.16K	Sell	33 -51	-61%	-$7.34K	﹤0.01%	7352
2022 Q3	$21K	Sell	84 -156	-65%	-$62.4K	﹤0.01%	6777
2022 Q2	$111K	Buy	240 +218	+991%	+$120K	﹤0.01%	6223
2022 Q1	$19K	Buy	22 +3	+16%	+$2.77K	﹤0.01%	7180
2021 Q4	$19K	Sell	19 -4	-17%	-$5.04K	﹤0.01%	7230
2021 Q3	$36K	Buy	23 +7	+44%	+$11.4K	﹤0.01%	6863
2021 Q2	$29K	Hold	16	–	–	﹤0.01%	6882
2021 Q1	$34K	Buy	+16	New	+$39.3K	﹤0.01%	6533
2020 Q3	–	Hold	0	–	–	–	6862
2020 Q2	–	Sell	-2	Closed	-$2.28K	–	6767
2020 Q1	$2K	Sell	2 -1	-33%	-$1.55K	﹤0.01%	6414
2019 Q4	$4K	Sell	3 -1	-25%	-$1.54K	﹤0.01%	6438
2019 Q3	$8K	Hold	4	–	–	﹤0.01%	6274
2019 Q2	$14K	Hold	4	–	–	﹤0.01%	6049
2019 Q1	$23K	Hold	4	–	–	﹤0.01%	5971
2018 Q4	$10K	Sell	4 -1	-20%	-$3.23K	﹤0.01%	6169
2018 Q3	$28K	Sell	5 -1	-17%	-$4K	﹤0.01%	6046
2018 Q2	$17K	Hold	6	–	–	﹤0.01%	6187
2018 Q1	$31K	Hold	6	–	–	﹤0.01%	6020
2017 Q4	$34K	Sell	6 -1	-14%	-$7.03K	﹤0.01%	5946
2017 Q3	$51K	Hold	7	–	–	﹤0.01%	5779
2017 Q2	$86K	Hold	7	–	–	﹤0.01%	5691
2017 Q1	$120K	Hold	7	–	–	﹤0.01%	5537
2016 Q4	$125K	Hold	7	–	–	﹤0.01%	5507
2016 Q3	$161K	Hold	7	–	–	﹤0.01%	5102
2016 Q2	$108K	Sell	7 -1	-13%	-$15.8K	﹤0.01%	5209
2016 Q1	$123K	Hold	8	–	–	﹤0.01%	5218
2015 Q4	$80K	Hold	8	–	–	﹤0.01%	5521
2015 Q3	$89K	Hold	8	–	–	﹤0.01%	5471
2015 Q2	$179K	Sell	8 -3	-27%	-$73.1K	﹤0.01%	5300
2015 Q1	$288K	Hold	11	–	–	﹤0.01%	5004
2014 Q4	$359K	Buy	11 +3	+38%	+$93.8K	﹤0.01%	4903
2014 Q3	$263K	Sell	8 -5	-38%	-$141K	﹤0.01%	4993
2014 Q2	$360K	Buy	13 +3	+30%	+$76.6K	﹤0.01%	4820
2014 Q1	$306K	Buy	10 +1	+11%	+$34.9K	﹤0.01%	4878
2013 Q4	$319K	Buy	9 +1	+13%	+$23.7K	﹤0.01%	4782
2013 Q3	$199K	Sell	8 -2	-20%	-$64.4K	﹤0.01%	4892
2013 Q2	$437K	Buy	+10	New	+$559K	﹤0.01%	4350

Other funds holding BIOL

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

KWA

Kellett Wealth Advisors Cincinnati, Ohio $215M AUM 22.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Morgan Stanley's BIOL Position: Q1 2024 in Review

Morgan Stanley sold out of Biolase, Inc. (BIOL) in Q1 2024, closing a stake of 28 shares — an estimated $32 sold.

Morgan Stanley first reported a position in BIOL in Q2 2013 and held it in 40 quarters. The position peaked at $437K in Q2 2013. 18 funds tracked by Wall St. Rank hold BIOL as of Q1 2024.

Morgan Stanley reported no remaining Biolase, Inc. position as of Q1 2024 after selling out during the quarter.
Morgan Stanley sold 28 Biolase, Inc. shares in Q1 2024, an estimated $32.
Morgan Stanley first reported a position in Biolase, Inc. in Q2 2013 and held it in 40 quarters.
Morgan Stanley's Biolase, Inc. position peaked at $437K in Q2 2013.
18 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.